Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
about
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsCaspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysisSafety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patientsVoriconazole: review of a broad spectrum triazole antifungal agent.Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.Caspofungin: an overview.Echinocandin antifungals: review and update.Experiences with the use of caspofungin in paediatric patients.A clinical review of echinocandins in pediatric patients.Caspofungin therapy in immunocompromised children and neonates.Current evidence of antifungal prophylaxis and therapy in pediatric patients.Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients.Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections.Invasive respiratory aspergillosis is a treatable disease with early diagnosis and aggressive therapy.A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.Compassionate use study of caspofungin in children with proven or suspected invasive mycosis or persistent febrile neutropenia.Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation.
P2860
Q30873926-8B2312F3-4D3C-4CF8-871F-688C344100F3Q34108585-A598C019-661B-4C2C-93C6-DCC3D3F9EF0BQ34322081-B6982B84-6C25-49C9-8C36-D0E190BA9C2AQ35799730-5D18ADF3-73B5-4897-AC49-100544B09EA7Q36164008-3264C915-1ABC-464F-882D-907C7FCD8DA6Q36271648-ED1CBD08-6CA8-4C79-A6EB-D8620CA3C151Q36278031-81CF2CC7-5624-46E3-8C78-9A262E5CF9ADQ36441524-8F1535F3-8669-4AFE-8298-3B470D16433EQ37159589-E75723A0-0D2E-43C5-9151-7F353E264D17Q37653647-09A4182F-3CD7-4E41-978E-86E7A4B42AFBQ37854725-A7BB6E3E-C703-4AF9-94B2-58974D292B46Q37885746-6BD86139-C41B-4DBE-B7CA-DAF13D406532Q39037978-BA8CF46B-7ED8-46EE-B8A3-5DADBDD0F944Q39215244-33EC5F23-D7FD-462B-9710-51400399AAE1Q40355575-2E0F3BB6-2CFB-4750-9422-E5FA61B09866Q43742898-667E1311-049C-44BD-B579-8E4436BF25DCQ46021270-B82EBC22-F0DE-4FCE-897C-23BC33CAACF4Q46653990-6C8AE66E-5406-40CB-BF51-996E07C556A9Q51186226-75C28124-75E3-465D-8D5B-7742647E75D6
P2860
Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@en
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@nl
type
label
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@en
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@nl
prefLabel
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@en
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@nl
P2093
P2860
P1476
Safety and efficacy of caspofu ...... y refractory invasive mycosis.
@en
P2093
Chiara Messina
Elisabetta Calore
Luigi Zanesco
Marta Pillon
Riccardo Cusinato
Rita Alaggio
Tiziana Toffolutti
P2860
P356
10.1111/J.1600-0609.2004.00254.X
P577
2004-07-01T00:00:00Z